Evidence map›Paper›PMID 32483304›Full record

ReviewNature reviews. Cardiology2020

Native and bioengineered extracellular vesicles for cardiovascular therapeutics.

Ricardo Cerqueira de Abreu, Hugo Fernandes, Paula A da Costa Martins, Susmita Sahoo, Costanza Emanueli, Lino Ferreira

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 271 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
271citing papers in PubMed, 2 pooled it
20.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

271 citing papers in PubMed, 2 syntheses or guidelines pooled it, 484 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Endogenous Engineering Reprograms Extracellular Vesicles for Enhanced Therapeutic Function.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. mRNA medicine for cardiovascular disease.Nature cardiovascular research · 2026
    Review
  18. Article
  19. Review
  20. Review

211 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 4 countries.

Ricardo Cerqueira de AbreuCARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.
Hugo FernandesFaculty of Medicine, University of Coimbra, Coimbra, Portugal.
Paula A da Costa MartinsCARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.ORCID http://orcid.org/0000-0002-0695-1187
Susmita SahooDivision of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Costanza EmanueliNational Heart & Lung Institute, Imperial College London, London, UK.
Lino FerreiraCNC-Centre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal. lino@uc-biotech.pt.
Maastricht University · NLUniversity of Coimbra · PTIcahn School of Medicine at Mount Sinai · USImperial College London · GB

Funding

Extracellular Vesicle-Encapsulated AAVs for Therapeutic Gene Delivery to the HeartR01HL148786 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Kiyotake Ishikawa, Susmita Sahoo · 2019 to 2026
$4.1M
Therapeutic Mechanisms of Human CD34 ExosomesR01HL124187 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SAHOO, SUSMITA · 2014 to 2018
$2.1M
Dysregulated Adenosine Methylation of mRNA as a Novel Mechanism of Heart FailureR01HL140469 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SAHOO, SUSMITA · 2018 to 2021
$1.7M
British Heart Foundation RG/20/9/35101NHLBI NIH HHS R01 HL124187NHLBI NIH HHS R01 HL140469NHLBI NIH HHS R01 HL148786
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are a heterogeneous group of natural particles that are relevant to the treatment of cardiovascular diseases. These endogenous vesicles have certain properties that allow them to survive in the extracellular space, bypass biological barriers and deliver their biologically active molecular cargo to recipient cells. Moreover, EVs can be bioengineered to increase their stability, bioactivity, presentation to acceptor cells and capacity for on-target binding at both cell-type-specific and tissue-specific levels. Bioengineering of EVs involves the modification of the donor cell before EV isolation or direct modification of the EV properties after isolation. The therapeutic potential of native EVs and bioengineered EVs has been only minimally explored in the context of cardiovascular diseases. Efforts to harness the therapeutic potential of EVs will require innovative approaches and a comprehensive integration of knowledge gathered from decades of research into molecular-compound delivery. In this Review, we outline the endogenous properties of EVs that make them natural delivery agents as well as the features that can be improved by bioengineering. We also discuss the therapeutic applications of native and bioengineered EVs to cardiovascular diseases and examine the opportunities and challenges that need to be addressed to advance this research area, with an emphasis on clinical translation.

Indexed as

BioengineeringRegenerationBrainCardiovascular DiseasesCell SurvivalExtracellular VesiclesExtremitiesHeartHumansIschemiaMicroRNAsMyocardial InfarctionMyocytes, CardiacParacrine CommunicationStem CellsStrokeMicroRNAs

Identifiers

PMID32483304
PMCPMC7874903
OpenAlexW3032105658

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.